Interim report HAEMATO AG second quarter 2017

11.09.2017
.
HAEMATO AG - Engl
Konzernnews
Aktuelles

HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of patent-free and patent-protected drugs primarily in the high-price indicative areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiac, circulatory diseases. In the first half-year of 2017, HAEMATO AG recorded significant sales growth. In addition, the development of innovative medical products for the beauty market was launched. HAEMATO AG assumes that the first products will be launched in the coming year, which has already created the basis for further growth and additional earnings.

The interim report published today on the reporting period from January 1, 2017 to June 30, 2017 is available for download at:

HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities is on the growth markets of patent-free and patent-protected med-icines. The focus is on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Ex-change. Key figures for the share of HAEMATO AG: